Viridian Therapeutics, Inc. VRDN
NASDAQ · United States · Health Technology
$18.99-1.60 (-7.77%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Viridian Therapeutics' (VRDN) Lumvoa is off to a "stronger start" than anticipated, RBC Capital Mark
WALTHAM, Mass., September 02, 2026--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced that senior management will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Tuesday, September 8, 2026, at 12:45pm ET.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Viridian Therapeutics (VRDN) is set to see "minimal" revenue growth in H2 before inflecting meaningf
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.